GTAEXS617 + paclitaxel + bevacizumab

GTAEXS617 + paclitaxel + bevacizumab is a combination regimen consisting of three agents: GTAEXS617 (identity/mechanism not characterized in the literature as of the current search), paclitaxel, and bevacizumab. Paclitaxel is a small molecule chemotherapeutic agent that stabilizes microtubules, thereby inhibiting cell division and inducing apoptosis. Bevacizumab is a humanized monoclonal antibody that targets and neutralizes vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. Both paclitaxel and bevacizumab are established drugs in oncology, used alone or in combination for the treatment of multiple solid tumors such as metastatic breast cancer, ovarian cancer, and non-squamous non-small cell lung cancer[1][2][4][5][7][8][9]. The synergistic combination of paclitaxel with bevacizumab enhances anti-tumor efficacy through concurrent cytotoxic and anti-angiogenic mechanisms, leading to improved response rates and progression-free survival in several cancer types[1][3][4][8][9]. The specific agent GTAEXS617 is not characterized in public sources as of September 2025; further information would be required for a full mechanistic or development profile of this component.